Login to Your Account



Panel's Vote Not Magic

Dendreon Takes Hit As FDA Calls For More Provenge Data

By Randall Osborne


Thursday, May 10, 2007
Bad news from the FDA for Dendreon Corp. on Provenge for prostate cancer sent the firm's stock into a tailspin and trimmed other cancer-vaccine companies' shares as well, taking away some of the gains made when an advisory panel gave the compound a positive vote in late March. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription